Myriad Genetics has made good on its promise to appeal a federal district court's recent determination that seven of its BRCA1/2 gene patents are invalid.
An appeals court has ruled in favor of Qiagen in an antitrust suit brought by Third Wave over HPV tests.
Cerenis, Montreal Heart Institute, UVA, Ortho Clinical, Mirna, UCSF, Case Western, Diagnostic Hybrids, iBridge Network, Ben Franklin Tech Partners, and more…
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.